Vahaticor Inc
The A-FLUX Reducer System by VahatiCor tackles the complexities of corononary microvascular dysfunction providing effective relief for patients suffering from chronic symptoms like chest pain and shortness of breath. Disclaimer: VahatiCor’s A-Flux Reducer System is an experimental treatment for investigational use only. It is not an approved treatment for ischemic heart disease in the United States.
7-day free trial · no credit card
Verified contacts
3
available on Kipplo
LinkedIn employees
10
1 to 10 range
Open roles
—
no listings
Distinct roles
3
indexed titles
Tech stack
1
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 3 verified contacts at Vahaticor Inc
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
3 contacts with verified email or phone · masked until revealed.
- MM
Michael Mandel
Head of Corporate Development · General Business & Management
EmailPhone - HE
Howard Edelman
Chief Executive Officer · General Business & Management
EmailPhone
Showing 2 of 3 verified contacts
Top roles at Vahaticor Inc
3 distinct titles indexed · top 3 shown.
- 1chief executive officer
- 1head of corporate development
- 1tioga cardiovascular
Sign up to unlock all 3 contacts at Vahaticor Inc
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 3 verified contacts at Vahaticor Inc
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.